Select publications

Carroll K et al. Trial 709. The ISEL study (Iressa® Survival Evaluation in Lung Cancer). Summary of data as of December 16, 2004. FDA presentation. Available at www.fda.gov/ ohrms/dockets/ac/05/slides/2005-4095S2_01_02-AstraZeneca-709-Survival_files/frame.htm. Accessed June 20, 2005.

Gefitinib (Iressa™) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. AstraZeneca press release, 17 December 2004. http://www.astrazeneca. com/pressrelease/4245.aspx

Miller VA et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Proc ASCO 2004;Abstract 7061.

Pao W et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17. Abstract

Perez-Soler R et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Proc ASCO 2005;Abstract LBA4.

Shepherd FA et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32. Abstract

Tsao MS et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract